Evidence map›Paper›PMID 27334118›Full record

ArticleCancer medicine2016

Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer.

Sasagu Kurozumi, Yuri Yamaguchi, Shin-Ichi Hayashi, Hiromi Hiyoshi, Tetsuji Suda, Tatsuyuki Gohno, Hiroshi Matsumoto, Hiroyuki Takei, Jun Horiguchi, Izumi Takeyoshi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. RNA mCancer communications (London, England) · 2025
    Article
  3. Review
  4. Clinical Implications ofInternational journal of medical sciences · 2021
    Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Sasagu KurozumiDivision of Breast Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.
Yuri YamaguchiResearch Institute for Clinical Oncology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.
Shin-Ichi HayashiDepartment of Molecular and Functional Dynamics, Tohoku University, 2-1 Seiryo-chou, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Hiromi HiyoshiCenter for Tsukuba Advanced Research Alliance, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Ibaraki, Japan.
Tetsuji SudaResearch Institute for Clinical Oncology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.
Tatsuyuki GohnoDepartment of Molecular and Functional Dynamics, Tohoku University, 2-1 Seiryo-chou, Aoba-ku, Sendai, 980-8575, Miyagi, Japan.
Hiroshi MatsumotoDivision of Breast Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.
Hiroyuki TakeiDivision of Breast Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.
Jun HoriguchiDepartment of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
Izumi TakeyoshiDepartment of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
Tetsunari OyamaDepartment of Diagnostic Pathology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, 371-8511, Gunma, Japan.
Masafumi KurosumiDepartment of Pathology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.
Saitama Cancer Center · JPGunma University · JPTohoku University · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The carboxyl terminus of the Hsc70-interacting protein (CHIP) is considered to induce the ubiquitination and degradation of several oncogenic proteins, and play a role in the inhibition of tumor progression and invasion under experimental conditions. However, the impact of CHIP expression on the prognosis of breast cancer patients has not yet been established. In this study, using an immunohistochemical method, 272 patients with invasive breast cancer were assessed for the expression of CHIP (graded scores 0-3) and the statuses of biomarkers, such as estrogen receptor (ER), progesterone receptor (PgR), and HER2. The relationships between the statuses of CHIP and biomarkers as well as clinical features were also evaluated, and that between the expression of CHIP and patient prognosis was analyzed. We revealed that the strong expression of CHIP correlated with positive ER (P < 0.001), positive PgR (P < 0.001), and negative HER2 (P = 0.02). In postmenopausal patients, relapse-free survival (RFS) was significantly better in the high CHIP group than in the low CHIP group (P = 0.042). In addition, RFS and cancer-specific survival (CSS) were significantly better in patients with ER-positive/CHIP score 3 tumors than in those with ER-negative/CHIP score 0 tumors (RFS: P = 0.038, CSS: P = 0.0098). The methylation status of CHIP gene promoter did not always account for the down-regulation of its expression. In conclusion, the overexpression of CHIP is a potent prognostic factor of a good prognosis in ER-positive breast cancer patients in the postmenopausal phase.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansMastectomyMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm ProteinsPostmenopausePrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesNeoplasm ProteinsReceptors, EstrogenReceptors, ProgesteroneSTUB1 protein, humanUbiquitin-Protein LigasesBreast cancercarboxyl terminus of the Hsc70-interacting protein (CHIP)postmenopausal patientsprognostic factor

Identifiers

PMID27334118
PMCPMC4971916
OpenAlexW2473910991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.